RANDOMIZED PHASE 3 STUDY OF LENVATINIB PLUS PEMBROLIZUMAB FOR ADVANCED ENDOMETRIAL CANCER (AEC): SUBGROUP ANALYSIS OF PATIENTS WITH DNA MISMATCH REPAIR DEFICIENT (DMMR) TUMORS
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER（2021）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要